|Articles|April 15, 2002
- BioPharm International-04-01-2002
- Volume 15
- Issue 4
Business Matters: Personalized Medicine or Blockbusterology?
Author(s)G. Steven Burrill
by G. Steven Burrill, Burrill & Company Biotechnology offers to change the face of medicine, if big pharma doesn't stand in the way
Advertisement
Articles in this issue
almost 24 years ago
Analytical Advances: Paperless or Less Paper?almost 24 years ago
Beyond QSITalmost 24 years ago
Determining Protein Concentration, Part 1: Methodologyalmost 24 years ago
Guest Editorial: The Protein Production Challengealmost 24 years ago
Advances in Amino Acid AnalysisNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
2
FAQ: What You Need to Know About Agentic AI in Drug Discovery
3
Coya Raises $11.1 Million to Advance Immunomodulatory ALS Program
4
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
5
